Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.

Annals of clinical and translational neurology(2023)

引用 1|浏览12
暂无评分
摘要
IRRs and AEs occurred at acceptable rates during in-home infusions of ocrelizumab over a shorter infusion time. Patients reported increased confidence and comfort with the home infusion process. Findings from this study provide evidence of the safety and feasibility of home-based ocrelizumab infusion over a shorter infusion period.
更多
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要